Proxima wants to move blood tests into the home, and it has cleared an important early hurdle
Algocyte’s Proxima is designed to run blood-count tests from a small finger-prick sample and send the results to a clinician in about 20 minutes. For patients who need frequent monitoring, that could mean fewer trips to a clinic or laboratory. The device has also moved beyond the concept stage.
- ▪Algocyte’s Proxima is designed to run blood-count tests from a small finger-prick sample and send the results to a clinician in about 20 minutes.
- ▪For patients who need frequent monitoring, that could mean fewer trips to a clinic or laboratory.
- ▪The device has also moved beyond the concept stage.
Digital Trends files mainly under tech. We currently carry 677 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Digital Trends |
| Canonical URL | https://www.digitaltrends.com/home/proxima-wants-to-move-blood-tests-into-the-home-and-it-has-cleared-an-important-early-hurdle/ |
| Publication time | Wed, 05 Aug 2026 13:49:09 +0000 |
| Retrieval time | 2026-08-05T13:50:41.885Z |
| Last seen | 2026-08-05T13:50:41.885Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 4SXcfft9CoCb · 1 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Algocyte’s Proxima is designed to run blood-count tests from a small finger-prick sample and send the results to a clinician in about 20 minutes. For patients who need frequent monitoring, that could mean fewer trips to a clinic or laboratory. The device has also moved beyond the concept stage. Proxima carries UK conformity credentials, while Algocyte operates under a certified medical-device quality system. Those steps give the project more weight than a prototype shown at a launch event. What Proxima actually does Proxima is an ultra-portable hematology analyzer built around a small blood sample. Algocyte says it can measure markers used in a partial or full blood count, including red and white blood cells, platelets, and hemoglobin. Algocyte A smartphone app controls the device.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Digital Trends.
Discussion
0 commentsMore from Digital Trends
